Cancer of Pancreas Clinical Trial
— PEAPPOfficial title:
Comparison Between Blumgart Anastomosis and Cattell Warren Anastomosis in Reduction of Post-Operative Complications After Pancreaticoduodenectomy Procedure
The aim of this study is to make a step for evaluation and presentation of a safe technique for pancreatico-jejunostomy that help in minimizing post-operative morbidity and mortality in pancreatic cancer patient by comparing Blumgart anastomosis with Cattell warren technique of anastomosis.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | December 2022 |
Est. primary completion date | December 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Known Pancreatic head cancer diagnosed radiologically. - Operable and borderline pancreatic cancer. - Patients who will undergo upfront surgery and those who received neoadjuvant chemotherapy are included. Exclusion Criteria: - Metastatic patients. - Locally advanced cases. - Patients with comorbidities who are unfit for major surgical procedures. - Patients with very small pancreatic duct where the pancreatic duct can't be identified. |
Country | Name | City | State |
---|---|---|---|
Egypt | The Egyptian National Cancer Institute | Cairo |
Lead Sponsor | Collaborator |
---|---|
Cairo University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Post-Operative Pancreatic Fistula | We used the International Study Group of Pancreatic Fistula (ISGPF) definition which is any measurable pancreatic fluid output after postoperative day 3 (containing more than three times the normal serum amylase level; more than 300 IU/L) with clinical signs of an infection and/or necessitating a change in clinical management. | Up to 10 days after the operation | |
Secondary | Biliary leakage | Any biliary output via percutaneous drains after the first postoperative day, or detected at a re-laparotomy | Up to 10 days after the operation | |
Secondary | Post-Operative bleeding | including early and late bleeding (1-3 weeks post-operative) According to ISGPF it is defined as any bleeding from the surgical site with a drop in hemoglobin concentration greater than 3 g/dL with peripheral circulatory impairment requiring medical, surgical, or radiological intervention. | 1-3 weeks | |
Secondary | Hospital Stay | the post operative hospital stay | Immediate after surgery and until the discharge of the patient ,including the readmission within the first 30 days after the operation | |
Secondary | Operative Time | Time of the surgical procedure in hours | During the operation | |
Secondary | primary or reactionary hemorrhage | Bleeding that occurs during or in the first day after the operation | During the operation and within the first 24 hours after the operation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02902484 -
Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04008537 -
Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device
|
N/A | |
Recruiting |
NCT04809935 -
EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy
|
Phase 4 | |
Not yet recruiting |
NCT03659292 -
Effects of Epidural Block on the Prognosis in Patients With Pancreatic Cancer Undergoing Distal Pancreatectomy
|
N/A | |
Completed |
NCT03150615 -
Enteral Nutrition After Pancreaticoduodenectomy
|
N/A | |
Recruiting |
NCT02682394 -
Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas
|
N/A | |
Recruiting |
NCT05566743 -
A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas
|
Phase 2 | |
Not yet recruiting |
NCT04049461 -
Heterotopic Ossification in Abdominal Incision and Pancreatic Cancer
|
||
Recruiting |
NCT04164602 -
The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
|
||
Active, not recruiting |
NCT04128332 -
Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer
|
N/A | |
Recruiting |
NCT03536793 -
Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
|
||
Recruiting |
NCT02311439 -
Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas
|
Phase 2/Phase 3 | |
Completed |
NCT02296736 -
The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan
|
||
Withdrawn |
NCT04123574 -
A Pilot Study of BXCL701 in Patients With Pancreatic Cancer
|
Early Phase 1 | |
Not yet recruiting |
NCT03278015 -
Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT02905578 -
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
|
Phase 2 | |
Completed |
NCT01446458 -
Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT04677244 -
Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level
|
N/A | |
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Recruiting |
NCT06148298 -
Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer
|